Stay updated on Tezepelumab in Chronic Urticaria Clinical Trial
Sign up to get notified when there's something new on the Tezepelumab in Chronic Urticaria Clinical Trial page.

Latest updates to the Tezepelumab in Chronic Urticaria Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page now presents the completed INCEPTION study of tezepelumab for chronic spontaneous urticaria, including its study design, eligibility criteria, outcome measures, and participating locations. It also provides the study publication, record history, and links to protocols and individual-participant-data sharing information.SummaryDifference100%

- Check14 days agoChange DetectedThe footer revision identifier changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedAn NIH-wide notice about updates to terminology for artificial intelligence appears above the page’s 403 error.SummaryDifference1%

- Check28 days agoChange DetectedThe site footer revision number changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site revision identifier changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe study page now shows a 403 Forbidden error screen, indicating the record is inaccessible, while the surrounding site chrome remains visible.SummaryDifference20%

Stay in the know with updates to Tezepelumab in Chronic Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tezepelumab in Chronic Urticaria Clinical Trial page.